Sionna Therapeutics Business Summary

Sionna Therapeutics, Inc. (SION) is a clinical-stage biopharmaceutical company primarily focused on the research and development of first-in-class small molecule therapies for cystic fibrosis (CF). The company operates as a single business segment, generating value through the advancement of its proprietary pipeline rather than immediate product sales; as of March 2026, it remains pre-revenue with a robust cash runway extending into 2028. Sionna’s business model centers on a dual-mechanism strategy that combines nucleotide-binding domain 1 (NBD1) stabilizers with complementary CFTR modulators to normalize protein function in patients with the ΔF508 mutation. Its primary direct competitors include Vertex Pharmaceuticals, Belite Bio, and Kymera Therapeutics. While Vertex currently dominates the $12 billion CF market, Sionna positions itself as a high-potential challenger by targeting NBD1, a critical site for the most common CF mutation that remains unaddressed by existing standard-of-care treatments. The leadership team is led by President and CEO Mike Cloonan, who previously served as COO of Sage Therapeutics and brought extensive experience in global commercialization. The executive suite includes Chief Financial Officer Elena Ridloff, formerly CFO of Acadia Pharmaceuticals, and Chief Medical Officer Charlotte McKee, M.D., a former Harvard Medical School faculty member and pulmonary specialist. The company’s scientific foundation is anchored by co-founders Greg Hurlbut, Ph.D. (SVP, Discovery Research) and Mark Munson, Ph.D. (SVP, Medicinal Chemistry), both of whom possess decades of expertise in CFTR biology. Sionna is backed by a high-pedigree board and investor base, including Independent Chairman Paul Clancy (former CFO of Biogen and Alexion) and Director Bruce Booth of Atlas Venture. Notable institutional investors include OrbiMed, Enavate Sciences, RA Capital Management, and the Cystic Fibrosis Foundation.